22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
On June 19, 2019, the New York State Assembly and Senate passed legislation that makes sweeping chan...
Read More >
What is a Reasonable Accommodation Under the ADA? Under the Americans With Disabilities Act, as amen...
Read More >
The New Jersey test for independent contractor status under the unemployment laws is already very to...
Read More >
In this second edition of October HorrorFest 2020 celebration we consider the first Hammer film vers...
Read More >
Executive Summary: The long-awaited decision from a federal judge in Massachusetts was released on S...
Read More >
EU COMPETITION LAW AND ARTIFICIAL INTELLIGENCE - Artificial Intelligence (AI) and big data are pla...
Read More >